title: The role of integrated F-18-FDG-PET scanning in the detection of M1 disease in oesophageal adenocarcinoma and impact on clinical management.
abstract: BACKGROUND
  The aim of this study was to evaluate the efficacy of F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) scanning in the staging of oesophageal adenocarcinoma.
  
  
  METHODS
  One hundred four patients with biopsy-proven adenocarcinoma underwent (18)F-FDG-PET scan. FDG avid lesions were further investigated to their diagnostic conclusion.
  
  
  RESULTS
  Nineteen patients (18.26%) were found to have non-loco-regional FDG uptake. Of the patients, 3.84% were found to have M1 disease and 7.69% were found to have a second primary tumour. The sensitivity and specificity of FDG-PET scanning to detect metastatic disease in our series was 57.14% and 84.53%, respectively. The overall diagnostic accuracy was 82.69%.
  
  
  CONCLUSIONS
  PET scanning improves staging and prevents unnecessary surgery in patients with M1 disease. It represents a good adjunct to computed tomography scanning and endoscopic ultrasound in the staging of oesophageal adenocarcinoma. The detection of asymptomatic coexisting synchronous cancers is an added benefit provided by PET scanning over similar diagnostic modalities.
authors.affiliation: Division of Upper GI Surgery, University College Hospital, 2B Maple House, 25 Grafton Way, London, WC1E 5DB, UK. soumil_v@yahoo.com
authors.forename: Soumil
authors.initials: S
authors.lastname: Vyas
authors.forename: Sheraz R
authors.initials: SR
authors.lastname: Markar
authors.forename: Lydia
authors.initials: L
authors.lastname: Iordanidou
authors.forename: Samantha
authors.initials: S
authors.lastname: Read
authors.forename: David
authors.initials: D
authors.lastname: Stoker
authors.forename: Majid
authors.initials: M
authors.lastname: Hashemi
authors.forename: Ian
authors.initials: I
authors.lastname: Mitchell
authors.forename: Mark
authors.initials: M
authors.lastname: Winslet
authors.forename: Jamshed
authors.initials: J
authors.lastname: Bomanji
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy; D003110:Colonic Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000000981:diagnostic imaging / Q000556:secondary / Q000628:therapy; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary / Q000628:therapy; D012680:Sensitivity and Specificity
chemical_list: D019788:Fluorodeoxyglucose F18